TCGA-ZF-AA4R-01A-11R-A38B-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 34.03416557
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.440
- E2F_TARGETS+0.390
- G2M_CHECKPOINT+0.350
- TGF_BETA_SIGNALING+0.310
- MITOTIC_SPINDLE+0.250
- PROTEIN_SECRETION+0.230
- MYOGENESIS+0.220
- ANGIOGENESIS+0.180
- APICAL_SURFACE+0.180
- APICAL_JUNCTION+0.170
Top 10 suppressed
- MYC_TARGETS_V2-0.490
- ALLOGRAFT_REJECTION-0.370
- IL6_JAK_STAT3_SIGNALING-0.360
- INFLAMMATORY_RESPONSE-0.360
- ADIPOGENESIS-0.310
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.310
- TNFA_SIGNALING_VIA_NFKB-0.310
- OXIDATIVE_PHOSPHORYLATION-0.300
- INTERFERON_GAMMA_RESPONSE-0.290
- INTERFERON_ALPHA_RESPONSE-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-B6-A0WT-01A-11R-A109-07 | — | B | 0.787 |
| 2 | TCGA-DQ-5631-01A-01R-1873-07 | — | — | 0.779 |
| 3 | 0918cbd5-edd0-41c8-8b67-677f35ad4611 | — | — | 0.771 |
| 4 | SRR8518210 | — | E | 0.766 |
| 5 | TCGA-OR-A5KO-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.766 |
| 6 | 50d521bc-fb39-4811-9126-09f092623809 | — | — | 0.750 |
| 7 | 20100144.Her2HRpos | — | D | 0.748 |
| 8 | ERR2208936 | — | — | 0.738 |
| 9 | TCGA-BH-A1EV-01A-11R-A137-07 | — | C | 0.737 |
| 10 | TCGA-91-6829-01A-21R-1858-07 | — | cohortA1 | 0.737 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.440 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.390 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.350 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.310 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.250 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.230 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.220 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.180 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.180 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.170 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.170 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.120 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.110 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.110 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.080 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.050 | Inavolisib | — uncovered |